Literature DB >> 3814492

Mitotic activity in non-Hodgkin's lymphoma. Relation to the Kiel classification and to prognosis.

M Akerman, L Brandt, A Johnson, H Olsson.   

Abstract

At histopathological diagnosis of non-Hodgkin's lymphoma (NHL) the mean number of mitoses in 10 high power fields (X 40) was determined in thin sections (2 micron) and designated 'mitotic index' (MI). In 38 patients the thymidine labelling index (LI) of the lymphoma cells was also determined. There was a close correlation between MIs and LIs (r = 0.81, P less than 0.001) indicating that MI reflects the proliferative activity in NHL. Among 101 patients with NHL classified according to the Kiel nomenclature MIs were generally lower in lymphomas of low grade malignant type than in the high grade malignant lymphomas. The variation of MIs within morphological subgroups was especially pronounced in high grade lymphomas. Only 18 of 49 patients (37%) with MI greater than or equal to 2 have survived for 2 years in contrast to 37 of 52 patients (77%) with MI less than 2 (P = 0.001). For patients with histologically low grade lymphomas and MI greater than or equal to 2.0 the median survival was 23 months and for those with MI less than 2.0 58 months (P = 0.09). Patients with high grade lymphomas and MI greater than or equal to 2.0 had a median survival of 15 months compared to 57 months for those with MI less than 2.0 (P = 0.04). In a multivariate analysis of 50 patients with centroblastic-centrocytic (CB-CC) or centroblastic (CB) lymphomas the importance of different prognostic factors was analysed. Among the variables age, MI, growth pattern (follicular vs. diffuse), cell type (CB-CC vs. CB), clinical stage (I vs. II-IV), initial chemotherapy (active vs. less active) only age and MI gave significant prognostic information. It is concluded that the assessment of mitoses in NHL gives prognostic information in addition to histopathologic classification. The method is simple and the proliferative activity and histopathological diagnosis can be ascertained routinely on the same occasion.

Entities:  

Mesh:

Year:  1987        PMID: 3814492      PMCID: PMC2002081          DOI: 10.1038/bjc.1987.41

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  13 in total

1.  Report of the Committee on Hodgkin's Disease Staging Classification.

Authors:  P P Carbone; H S Kaplan; K Musshoff; D W Smithers; M Tubiana
Journal:  Cancer Res       Date:  1971-11       Impact factor: 12.701

2.  Uptake of thymidine in lymphoma cells obtained through fine-needle aspiration biopsy. Relation to prognosis in non-Hodgkin's lymphomas.

Authors:  L Brandt; H Olsson; M Monti
Journal:  Eur J Cancer Clin Oncol       Date:  1981-11

3.  Morphologic classification of non-Hodgkin's lymphoma. I. Retrospective analysis using the Kiel classification.

Authors:  B Glimelius; C Sundström
Journal:  Acta Radiol Oncol       Date:  1982

4.  Growth fractions in malignant non-Hodgkin's lymphomas (NHL) as determined in situ with the monoclonal antibody Ki-67.

Authors:  J Gerdes; F Dallenbach; K Lennert; H Lemke; H Stein
Journal:  Hematol Oncol       Date:  1984 Oct-Dec       Impact factor: 5.271

Review 5.  Clinical and prognostic relevance of the Kiel classification of non-Hodgkin lymphomas results of a prospective multicenter study by the Kiel Lymphoma Study Group.

Authors:  G Brittinger; H Bartels; H Common; E Dühmke; H H Fülle; U Gunzer; T Gyenes; R Heinz; E König; P Meusers
Journal:  Hematol Oncol       Date:  1984 Jul-Sep       Impact factor: 5.271

6.  A retrospective clinico-pathologic study of non-Hodgkin's lymphomas classified according to the nomenclatures of Lennert and of Rappaport.

Authors:  E Cavallin-Ståhl; T Landberg; L G Lindberg; M Akerman
Journal:  Acta Med Scand       Date:  1981

7.  3H-thymidine uptake in B cell lymphomas--relationship to treatment response and survival.

Authors:  S Kvaløy; P F Marton; O Kaalhus; J Høie; A Foss-Abrahamsen; T Godal
Journal:  Scand J Haematol       Date:  1985-05

8.  Morphological classification of non-Hodgkin malignant lymphoma. II. Comparison between Rappaport's classification and the Kiel classification.

Authors:  B Glimelius; H Hagberg; C Sundström
Journal:  Scand J Haematol       Date:  1983-01

9.  Labeling index as a prognostic marker in non-Hodgkin's lymphomas.

Authors:  A Costa; G Bonadonna; E Villa; P Valagussa; R Silvestrini
Journal:  J Natl Cancer Inst       Date:  1981-01       Impact factor: 13.506

10.  The use of serum deoxythymidine kinase as a prognostic marker, and in the monitoring of patients with non-Hodgkin's lymphoma.

Authors:  J S Gronowitz; H Hagberg; C F Källander; B Simonsson
Journal:  Br J Cancer       Date:  1983-04       Impact factor: 7.640

View more
  14 in total

Review 1.  Proliferation markers in tumours: interpretation and clinical value.

Authors:  P J van Diest; G Brugal; J P Baak
Journal:  J Clin Pathol       Date:  1998-10       Impact factor: 3.411

2.  DNA flow cytometry of follicular non-Hodgkin's lymphoma.

Authors:  J C Macartney; R S Camplejohn; R Morris; K Hollowood; D Clarke; A Timothy
Journal:  J Clin Pathol       Date:  1991-03       Impact factor: 3.411

Review 3.  Proliferation indices in malignant lymphomas.

Authors:  J Crocker
Journal:  Clin Exp Immunol       Date:  1989-09       Impact factor: 4.330

Review 4.  Review: assessment of cell proliferation in histological material.

Authors:  P A Hall; D A Levison
Journal:  J Clin Pathol       Date:  1990-03       Impact factor: 3.411

5.  Does delay in fixation affect the number of mitotic figures in processed tissue?

Authors:  S S Cross; R D Start; J H Smith
Journal:  J Clin Pathol       Date:  1990-07       Impact factor: 3.411

6.  Cell proliferation in non-Hodgkin's lymphomas. Digital image analysis of Ki-67 antibody staining.

Authors:  B R Schwartz; G Pinkus; S Bacus; M Toder; D S Weinberg
Journal:  Am J Pathol       Date:  1989-02       Impact factor: 4.307

7.  Prognostic indicators in centroblastic-centrocytic lymphoma.

Authors:  N R Griffin; M R Howard; P Quirke; C J O'Brien; J A Child; C C Bird
Journal:  J Clin Pathol       Date:  1988-08       Impact factor: 3.411

8.  Prognostic significance of Ki67 and its correlation with mitotic index in dogs with diffuse large B-cell lymphoma treated with 19-week CHOP-based protocol.

Authors:  Oscar R Sierra Matiz; Juliana Santilli; Leticia A Anai; Maria C L Da Silva; Felipe A Sueiro; Júlio L Sequeira; Larissa F Magalhães; Geórgia M Magalhães; Mirela Tinucci Costa; Sabryna G Calazans
Journal:  J Vet Diagn Invest       Date:  2017-12-01       Impact factor: 1.279

9.  Correlations between apoptotic and proliferative indices in malignant non-Hodgkin's lymphomas.

Authors:  L Leoncini; M T Del Vecchio; T Megha; P Barbini; P Galieni; S Pileri; E Sabattini; F Gherlinzoni; P Tosi; R Kraft
Journal:  Am J Pathol       Date:  1993-03       Impact factor: 4.307

10.  Expression of Ki-67 nuclear antigen in B and T cell lymphoproliferative disorders.

Authors:  N de Melo; E Matutes; I Cordone; R Morilla; D Catovksy
Journal:  J Clin Pathol       Date:  1992-08       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.